Short course treatment for MDR TB: jumping the gun? by Turkova, Anna & Kampmann, Beate
LSHTM Research Online
Turkova, Anna; Kampmann, Beate; (2017) Short course treatment for MDR TB: jumping the gun?
THORAX, 72 (9). p. 773. ISSN 0040-6376 DOI: https://doi.org/10.1136/thoraxjnl-2017-210163
Downloaded from: http://researchonline.lshtm.ac.uk/4650740/
DOI: https://doi.org/10.1136/thoraxjnl-2017-210163
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
https://researchonline.lshtm.ac.uk
Short course treatment for MDR TB:
jumping the gun?
Anna Turkova,1 Beate Kampmann2
Multidrug-resistant (MDR)-TB is threaten-
ing TB control worldwide. The conven-
tional treatment lasts 20–24 months, is
often toxic and half of the treated patients
have poor outcomes. WHO has recently
recommended a shorter regimen with
treatment duration of 9–12 months, aim-
ing for higher effectiveness, tolerability,
adherence and completion rates.1 This
shorter regimen is recommended for pat-
ients with pulmonary TB who have not
been previously exposed to second-line
drugs for more than 1 month and have no
conﬁrmed or suspected resistance to drugs
in the regimen, except high-dose isonia-
zid. Recommendations were based on the
promising results of large observational
cohorts in Asia and Africa.
In Thorax, Yanina Balabanova and col-
leagues assessed the proportion of adult
smear-positive pulmonary MDR-TB cases
who might have been eligible for the
shorter regimen. The patients were ini-
tially recruited in 2007 and 2009 and fol-
lowed up till 2012 in four eastern
European countries, who participated in
the European Union-funded TB-PAN-
NET (Pan-European network for the
study and clinical management of drug
resistant tuberculosis) project.2 Given the
drug sensitivity test results and the history
of previous treatment with second-line
drugs in this group of patients, the
authors concluded that only 4.2% of the
patients would have been eligible for the
shorter WHO regimen. The results of this
study were similar to other European and
Latin American cohorts.3
The WHO European region has one of
the highest burdens of MDR-TB in the
world with alarmingly high MDR-TB inci-
dence rates and the highest proportions of
MDR-TB among new and previously
treated cases.4 While the potential beneﬁts
of the shorter regimen on individual
patients and healthcare systems cannot be
underestimated, the effect might be minimal
or even negative, given the lower treatment
success rate and/or the high proportion of
ineligible patients for the shorter course.
As the authors state, the results of this
study should be conﬁrmed by similar eva-
luations in recent national surveillance
projects. These might enable appropriate
extrapolations for the region. Given the
high prevalence of resistance to pyrazina-
mide and increasing rates of resistance to
second-line drugs in the European region,
there are concerns that a limited number
of patients would fulﬁl the eligibility
criteria for the shorter WHO regimen.
The WHO guidelines highlight the
need to exclude resistance to ﬂuoroquino-
lones and injectables before starting treat-
ment and promote rapid second-line
molecular tests.1 However, these tests are
available only in central and regional-level
laboratories, and therefore the use of the
shorter regimen in practice may be limited
to a few treatment centres with good
access to diagnostics. Policy-makers are
currently reluctant to implement a guid-
ance with conditional recommendation
and very low certainty in evidence, and
are waiting for the deﬁnitive results of the
STREAM 1 trial, an ongoing randomised
controlled trial, directly comparing the
efﬁcacy and safety of the regimens.5
The increasing prevalence of MDR-TB
and limited access to drug susceptibility
testing make the pursuit for short, safe,
affordable and injection-free regimens
extremely important. The 9–12 month
regimen is only a ﬁrst step in the right direc-
tion. With few new and repurposed drugs
registered, some drugs in development and
a number of randomised controlled trials
ongoing, hopefully deﬁnitive evidence for
optimal MDR-TB treatment regimens will
emerge in the near future. To establish that
such regimens are ﬁt for purpose in differ-
ent geographical regions remains important
if we are to avoid further development of
antimicrobial resistance and poor outcome
in the context of TB.
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